Search

Displaying results 3561 - 3570 of 10000 in total
  1. Drug

    Dinoprost tromethamine

    go.drugbank.com/drugs/DB01160
    ApprovedVet approvedWithdrawn

    The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol...

  2. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).

  3. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before … being acquired by Implicit Bioscience in 2005.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

  5. Drug

    Tozasertib

    go.drugbank.com/drugs/DB19675
    Investigational

    Tozasertib has a monoisotopic molecular weight of 464.21 Da. … Tozasertib is under investigation in clinical trial NCT02532868 (A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)).

  6. Drug

    Zelicapavir

    go.drugbank.com/drugs/DB21662
    Investigational

    Zelicapavir has a monoisotopic molecular weight of 549.17 Da. … Zelicapavir is under investigation in clinical trial NCT06601192 (A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults).

  7. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  8. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.

  9. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine has a monoisotopic molecular weight of 691.29 Da. … Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).

  10. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.